Key Points
- COO Scott Lish sold 25,000 shares on Nov. 20 at an average price of $19.80 for about $495,000, trimming his stake to 672,207 shares (a 3.59% decrease).
- Alphatec shares traded up roughly 3.6% to $20.31 on elevated volume (~2.31 million shares), valuing the company at about $3.02 billion.
- Quarterly results beat expectations—$0.03 EPS versus a -$0.06 consensus and $196.5M revenue (up 30.4% YoY)—and analysts maintain a consensus "Moderate Buy" with an average target near $22.
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 25,000 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $19.80, for a total transaction of $495,000.00. Following the sale, the chief operating officer owned 672,207 shares of the company's stock, valued at approximately $13,309,698.60. This represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Alphatec Trading Up 3.6%
NASDAQ:ATEC traded up $0.70 during mid-day trading on Friday, reaching $20.31. 2,306,833 shares of the company's stock traded hands, compared to its average volume of 2,126,413. The company has a 50 day moving average price of $16.48 and a 200-day moving average price of $14.17. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -17.97 and a beta of 1.17. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. Alphatec Holdings, Inc. has a 12-month low of $8.69 and a 12-month high of $21.16.
Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.09. The business had revenue of $196.50 million during the quarter, compared to analysts' expectations of $182.78 million. The company's quarterly revenue was up 30.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.
Institutional Trading of Alphatec
A number of hedge funds have recently modified their holdings of ATEC. Nuveen LLC purchased a new stake in shares of Alphatec in the 1st quarter worth about $135,874,000. Granite Investment Partners LLC boosted its stake in Alphatec by 320.6% during the second quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company's stock worth $19,102,000 after acquiring an additional 1,311,748 shares in the last quarter. MetLife Investment Management LLC grew its holdings in Alphatec by 1,818.5% in the first quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company's stock worth $12,309,000 after purchasing an additional 1,150,669 shares during the period. Driehaus Capital Management LLC bought a new position in shares of Alphatec during the first quarter valued at approximately $10,398,000. Finally, Motley Fool Wealth Management LLC bought a new position in shares of Alphatec during the first quarter valued at approximately $9,070,000. Institutional investors own 66.35% of the company's stock.
Analyst Ratings Changes
Several analysts recently weighed in on the stock. HC Wainwright lifted their price target on shares of Alphatec from $20.00 to $24.00 and gave the company a "buy" rating in a report on Friday, October 31st. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Alphatec in a research report on Monday. Lake Street Capital set a $25.00 target price on shares of Alphatec and gave the company a "buy" rating in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Alphatec from a "hold" rating to a "buy" rating in a research report on Saturday, October 18th. Finally, Wells Fargo & Company raised their price objective on shares of Alphatec from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Thursday, October 16th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alphatec has a consensus rating of "Moderate Buy" and a consensus target price of $22.00.
Check Out Our Latest Report on Alphatec
Alphatec Company Profile
(
Get Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
